Cargando…
Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks
BACKGROUND: A higher proportion of intermittent viremia (to have a HIV-1 RNA viral load>50 copies/mL not confirmed) was reported in the boosted protease inhibitor monotherapy arm in some studies including MONOI trial, and that could have an impact on the replenishment of the HIV-1 DNA reservoirs....
Autores principales: | Lambert-Niclot, Sidonie, Flandre, Philippe, Valantin, Marc-Antoine, Soulie, Cathia, Fourati, Slim, Wirden, Marc, Sayon, Sophie, Pakianather, Sophie, Bocket, Laurence, Masquelier, Bernard, Dos Santos, Georges, Katlama, Christine, Calvez, Vincent, Marcelin, Anne-Genevieve |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405120/ https://www.ncbi.nlm.nih.gov/pubmed/22848481 http://dx.doi.org/10.1371/journal.pone.0041390 |
Ejemplares similares
-
Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010) -
INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels
por: Lambert-Niclot, Sidonie, et al.
Publicado: (2019) -
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2021) -
High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area: Seroprevalence of SARS-CoV-2 in HIV patients
por: ABDI, Basma, et al.
Publicado: (2022) -
Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)